<DOC>
	<DOCNO>NCT02012933</DOCNO>
	<brief_summary>Lambert-Eaton Myasthenic Syndrome ( LEMS ) rare autoimmune disorder affect nerve-muscle junction . The major symptom LEMS progressive muscle weakness . Many patient experience symptom like dry mouth impotence . Congenital Myasthenia ( CM ) inherit disorder similar affect symptom . 3,4-Diaminopyridine ( DAP ) experimental drug improve strength subject ( LEMS ) . There accepted treatment LEMS DAP relatively side effect .</brief_summary>
	<brief_title>3,4-Diaminopyridine Lambert-Eaton Myasthenic Syndrome ( LEMS ) Congenital Myasthenia ( CM )</brief_title>
	<detailed_description>Subjects clinically confirm LEMS CM receive 3,4-diaminopyridine ( 3,4 DAP ) mouth slowly increase dos . Treatment begin 5-10 mg three time day . A common final dosage 15-20 mg four five time day , clinically need , tolerate . The upper limit total 100 mg/day . Subjects monitor strength side effect via routine clinic visit interval one month first three month , every three month first year , least every six month thereafter . Treatment continue indefinitely good clinical response achieve side effect tolerable .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>Myasthenic Syndromes , Congenital</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Diagnosis LEMS CM If female age 9 , must negative pregnancy test , , premenopausal , must willing practice effective form birth control . Must test find ECG prolong QTc syndrome . Must agree second ECG time peak drug effect . Known sensitivity 3,4DAP History clinical seizure evidence seizure activity screen EEG History severe asthma</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>3,4DAP , LEMS , CM</keyword>
</DOC>